|
US20080281041A1
(en)
*
|
1999-06-07 |
2008-11-13 |
Rozema David B |
Reversibly Masked Polymers
|
|
US9879266B2
(en)
|
2002-11-14 |
2018-01-30 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
KR101141544B1
(ko)
|
2009-03-13 |
2012-05-03 |
한국과학기술원 |
에스아이알엔에이 다중 접합체 및 이의 제조방법
|
|
JP2012520085A
(ja)
*
|
2009-03-13 |
2012-09-06 |
エーゲン、インコーポレイテッド |
生物活性ｒｎａの送達のための組成物及び方法
|
|
SI2539451T1
(sl)
*
|
2010-02-24 |
2016-04-29 |
Arrowhead Research Corporation |
Sestavki za ciljano dostavo sirna
|
|
US10913767B2
(en)
*
|
2010-04-22 |
2021-02-09 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising acyclic and abasic nucleosides and analogs
|
|
WO2012019168A2
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP2625189B1
(en)
|
2010-10-01 |
2018-06-27 |
ModernaTX, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
AU2011343664B2
(en)
|
2010-12-17 |
2015-10-08 |
Arrowhead Pharmaceuticals, Inc. |
Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA
|
|
US8501930B2
(en)
|
2010-12-17 |
2013-08-06 |
Arrowhead Madison Inc. |
Peptide-based in vivo siRNA delivery system
|
|
CA3131967A1
(en)
|
2010-12-29 |
2012-07-05 |
F. Hoffman-La Roche Ag |
Small molecule conjugates for intracellular delivery of nucleic acids
|
|
AU2012236099A1
(en)
|
2011-03-31 |
2013-10-03 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
US9481661B2
(en)
|
2011-06-17 |
2016-11-01 |
Arrowhead Madison, Inc. |
Disubstituted maleic anhydrides with altered kinetics of ring closure
|
|
WO2013032829A1
(en)
|
2011-08-26 |
2013-03-07 |
Arrowhead Research Corporation |
Poly(vinyl ester) polymers for in vivo nucleic acid delivery
|
|
EP2807216A4
(en)
*
|
2011-08-26 |
2015-10-28 |
Arrowhead Res Corp |
POLY (VINYLESTER) POLYMERS FOR IN VIVO NUCLEIC ACID RELIEF
|
|
WO2013033230A1
(en)
|
2011-08-29 |
2013-03-07 |
Isis Pharmaceuticals, Inc. |
Oligomer-conjugate complexes and their use
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
DE19216461T1
(de)
|
2011-10-03 |
2021-10-07 |
Modernatx, Inc. |
Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
|
|
CA3018046A1
(en)
|
2011-12-16 |
2013-06-20 |
Moderna Therapeutics, Inc. |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
|
AU2012358181A1
(en)
*
|
2011-12-23 |
2014-07-10 |
Egen, Inc. |
Compositions and methods for the delivery of biologically active RNAs
|
|
WO2013102878A2
(en)
|
2012-01-05 |
2013-07-11 |
Department Of Biotechnology (Dbt) |
Fat1 gene in cancer and inflammation
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
WO2013151665A2
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins associated with human disease
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
US9133461B2
(en)
*
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
|
EP2838544A4
(en)
*
|
2012-04-18 |
2015-10-14 |
Arrowhead Res Corp |
POLY (ACRYLATE) POLYMERS FOR IN VIVO NUCLEIC ACID ADMINISTRATION
|
|
CA2842041A1
(en)
|
2012-04-18 |
2013-10-24 |
Arrowhead Research Corporation |
Poly(acrylate) polymers for in vivo nucleic acid delivery
|
|
US9127274B2
(en)
*
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
|
TW201808342A
(zh)
*
|
2012-05-02 |
2018-03-16 |
喜納製藥公司 |
包含四ｇａｌｎａｃ之新穎結合物及傳送寡核苷酸之方法
|
|
AR090905A1
(es)
*
|
2012-05-02 |
2014-12-17 |
Merck Sharp & Dohme |
Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica
|
|
US10323279B2
(en)
*
|
2012-08-14 |
2019-06-18 |
10X Genomics, Inc. |
Methods and systems for processing polynucleotides
|
|
AU2013302756C1
(en)
|
2012-08-14 |
2018-05-17 |
10X Genomics, Inc. |
Microcapsule compositions and methods
|
|
US9801953B2
(en)
|
2012-10-15 |
2017-10-31 |
Emory University |
Nanoparticles carrying nucleic acid cassettes for expressing RNA
|
|
CN104837996A
(zh)
|
2012-11-15 |
2015-08-12 |
罗氏创新中心哥本哈根有限公司 |
抗apob反义缀合物化合物
|
|
PL2922554T3
(pl)
|
2012-11-26 |
2022-06-20 |
Modernatx, Inc. |
Na zmodyfikowany na końcach
|
|
CA2900238A1
(en)
*
|
2013-02-22 |
2014-08-28 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) molecules containing a 2' internucleoside linkage
|
|
CN105247051A
(zh)
|
2013-02-28 |
2016-01-13 |
箭头研究公司 |
治疗epas1相关疾病的有机组合物
|
|
WO2014152211A1
(en)
|
2013-03-14 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
DK2992098T3
(da)
|
2013-05-01 |
2019-06-17 |
Ionis Pharmaceuticals Inc |
Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression
|
|
US9506030B2
(en)
|
2013-05-01 |
2016-11-29 |
Regulus Therapeutics Inc. |
Compounds and methods for enhanced cellular uptake
|
|
SG10201803157XA
(en)
|
2013-05-01 |
2018-05-30 |
Regulus Therapeutics Inc |
Microrna compounds and methods for modulating mir-122
|
|
WO2015021092A1
(en)
|
2013-08-07 |
2015-02-12 |
Arrowhead Research Corporation |
Polyconjugates for delivery of rnai triggers to tumor cells in vivo
|
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
EP3052521A1
(en)
|
2013-10-03 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
|
LT3052628T
(lt)
|
2013-10-04 |
2020-09-10 |
Alnylam Pharmaceuticals, Inc. |
Kompozicijos ir būdai alas1 geno raiškai nuslopinti
|
|
US9994846B2
(en)
|
2013-10-25 |
2018-06-12 |
Regulus Therapeutics Inc. |
MicroRNA compounds and methods for modulating miR-21 activity
|
|
MX2016005855A
(es)
*
|
2013-11-14 |
2016-07-13 |
Roche Innovation Ct Copenhagen As |
Compuestos de conjugados antisentido de apolipoproteina b (apob).
|
|
WO2015168172A1
(en)
|
2014-04-28 |
2015-11-05 |
Isis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds
|
|
BR112016022742B1
(pt)
|
2014-05-01 |
2022-06-14 |
Ionis Pharmaceuticals, Inc |
Composto químico, composição compreendendo o composto e uso dos mesmos
|
|
HUE052709T2
(hu)
|
2014-05-01 |
2021-05-28 |
Ionis Pharmaceuticals Inc |
Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására
|
|
US9382540B2
(en)
|
2014-05-01 |
2016-07-05 |
Isis Pharmaceuticals, Inc |
Compositions and methods for modulating angiopoietin-like 3 expression
|
|
EA036496B1
(ru)
|
2014-05-01 |
2020-11-17 |
Ионис Фармасьютикалз, Инк. |
Конъюгированные олигонуклеотиды для модулирования экспрессии фактора комплемента b
|
|
KR102589295B1
(ko)
|
2014-05-14 |
2023-10-13 |
타르그이뮨 테라퓨틱스 아게 |
개선된 폴리에틸렌이민 폴리에틸렌글리콜 벡터
|
|
WO2015179693A1
(en)
|
2014-05-22 |
2015-11-26 |
Isis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
EP3151839A4
(en)
*
|
2014-06-06 |
2018-02-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for enhanced intestinal absorption of conjugated oligomeric compounds
|
|
TW201620526A
(zh)
|
2014-06-17 |
2016-06-16 |
愛羅海德研究公司 |
用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
|
|
KR20170033439A
(ko)
|
2014-08-07 |
2017-03-24 |
레굴루스 테라퓨틱스 인크 |
대사 장애에 대한 마이크로rna의 표적화
|
|
US10436802B2
(en)
|
2014-09-12 |
2019-10-08 |
Biogen Ma Inc. |
Methods for treating spinal muscular atrophy
|
|
TW202503057A
(zh)
*
|
2014-10-10 |
2025-01-16 |
美商艾爾妮蘭製藥公司 |
用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法
|
|
AU2015330670B2
(en)
|
2014-10-10 |
2022-01-06 |
Novo Nordisk Health Care Ag |
Therapeutic inhibition of lactate dehydrogenase and agents therefor
|
|
CN106795200B
(zh)
|
2014-10-10 |
2020-06-19 |
豪夫迈·罗氏有限公司 |
Galnac亚磷酰胺、其核酸缀合物及其用途
|
|
WO2016061487A1
(en)
*
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
|
EP3221445B1
(en)
|
2014-11-20 |
2021-07-14 |
The Regents of The University of California |
Compositions and methods related to hematologic recovery
|
|
WO2016138132A1
(en)
*
|
2015-02-25 |
2016-09-01 |
The Trustees Of Columbia University In The City Of New York |
Dipeptidyl peptidase-iv(dpp4) inhibitors, methods and compositions for suppressing adipose tissue inflammation
|
|
CA2979703A1
(en)
*
|
2015-03-17 |
2016-09-22 |
Arrowhead Pharmaceuticals, Inc. |
Compositions and methods for inhibiting gene expression of factor xii
|
|
AR104754A1
(es)
|
2015-05-29 |
2017-08-09 |
Arrowhead Pharmaceuticals Inc |
Agentes de unión de tetrapéptido escindibles biológicamente
|
|
IL316159A
(en)
|
2015-06-15 |
2024-12-01 |
Mpeg La Llc |
Defined Oligonucleotide Multimers and Methods for Manufacture Thereof
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
WO2016205749A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
MX2018000412A
(es)
|
2015-07-10 |
2018-03-14 |
Ionis Pharmaceuticals Inc |
Moduladores de diaciglicerol aciltransferasa 2 (dgat2).
|
|
KR102579520B1
(ko)
|
2015-08-06 |
2023-09-15 |
에프. 호프만-라 로슈 아게 |
Galnac 산 유도체의 제조 방법
|
|
AU2016306275A1
(en)
|
2015-08-07 |
2018-02-08 |
Arrowhead Pharmaceuticals, Inc. |
RNAi therapy for Hepatitis B virus infection
|
|
CN108513588A
(zh)
|
2015-09-24 |
2018-09-07 |
Ionis制药公司 |
Kras表达的调节剂
|
|
JOP20160211B1
(ar)
|
2015-10-01 |
2021-08-17 |
Arrowhead Pharmaceuticals Inc |
تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
|
|
KR20250078597A
(ko)
|
2015-11-06 |
2025-06-02 |
아이오니스 파마수티컬즈, 인코포레이티드 |
아포리포프로테인 (a) 발현 조정
|
|
PL4119569T3
(pl)
|
2015-11-06 |
2024-11-18 |
Ionis Pharmaceuticals, Inc. |
Sprzężone związki antysensowne do zastosowania w terapii
|
|
BR112018003910B1
(pt)
|
2015-11-16 |
2022-03-22 |
F. Hoffmann-La Roche Ag |
Derivado de fosforamidita galnac, processo para a preparação de um derivado de fosforamidita galnac de fórmula i e uso dos derivados de fosforamidita galnac de fórmula i
|
|
JP7027311B2
(ja)
|
2015-11-16 |
2022-03-01 |
オリックス ファーマシューティカルズ，インコーポレーテッド |
ＭｙＤ８８又はＴＬＲ３を標的とするＲＮＡ複合体を使用した加齢黄斑変性の治療
|
|
KR20180095843A
(ko)
|
2015-12-07 |
2018-08-28 |
젠자임 코포레이션 |
Serpinc1-연관 장애의 치료를 위한 방법 및 조성물
|
|
US12110490B2
(en)
|
2015-12-18 |
2024-10-08 |
The Broad Institute, Inc. |
CRISPR enzymes and systems
|
|
JP6944942B2
(ja)
|
2016-02-02 |
2021-10-06 |
オリックス ファーマシューティカルズ，インコーポレーテッド |
ＩＬ４Ｒα、ＴＲＰＡ１、またはＦ２ＲＬ１を標的とするＲＮＡ複合体を用いたアトピー性皮膚炎および喘息の治療
|
|
CA3011946A1
(en)
|
2016-03-07 |
2017-09-14 |
Arrowhead Pharmaceuticals, Inc. |
Targeting ligands for therapeutic compounds
|
|
US10407469B2
(en)
|
2016-04-01 |
2019-09-10 |
Northwestern University |
Programmable polypeptide and nucleic acid nanoparticles
|
|
CA3020585A1
(en)
|
2016-04-11 |
2017-10-19 |
Arbutus Biopharma Corporation |
Targeted nucleic acid conjugate compositions
|
|
WO2017178656A1
(en)
|
2016-04-14 |
2017-10-19 |
Roche Innovation Center Copenhagen A/S |
TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE
|
|
KR20260004568A
(ko)
|
2016-04-19 |
2026-01-08 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신규한 crispr 효소 및 시스템
|
|
EP3445853A1
(en)
|
2016-04-19 |
2019-02-27 |
The Broad Institute, Inc. |
Cpf1 complexes with reduced indel activity
|
|
BR112018071997A2
(pt)
|
2016-04-26 |
2019-02-12 |
Viaqua Therapeutics Ltd |
nanopartícula de quitosana-rna, nanopartícula de quitosana-dsrna, composição nutracêutica, crustáceo criado em cativeiro, e método de tratamento ou prevenção de uma doença ou condição em um crustáceo criado em cativeiro associado a um vírus patogênico
|
|
MX2018015109A
(es)
|
2016-06-06 |
2019-04-22 |
Arrowhead Pharmaceuticals Inc |
Nucleotidos modificados con 5'-ciclo-fosfonato.
|
|
EP3484524B1
(en)
|
2016-07-15 |
2022-11-09 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of smn2
|
|
WO2018017814A1
(en)
|
2016-07-20 |
2018-01-25 |
President And Fellows Of Harvard College |
Peptidoglycan glycosyltransferase inhibitors of sed proteins for treating bacterial infections
|
|
JOP20190015A1
(ar)
|
2016-08-04 |
2019-02-04 |
Arrowhead Pharmaceuticals Inc |
عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
|
|
SG11201901841TA
(en)
*
|
2016-09-02 |
2019-03-28 |
Arrowhead Pharmaceuticals Inc |
Targeting ligands
|
|
WO2018053142A2
(en)
|
2016-09-14 |
2018-03-22 |
President And Fellows Of Harvard College |
Methods and compositions for modulating erythropoiesis
|
|
US11400161B2
(en)
|
2016-10-06 |
2022-08-02 |
Ionis Pharmaceuticals, Inc. |
Method of conjugating oligomeric compounds
|
|
WO2018112032A1
(en)
|
2016-12-13 |
2018-06-21 |
President And Fellows Of Harvard College |
Methods and compositions for targeting tumor-infiltrating tregs using inhibitors of ccr8 and tnfrsf8
|
|
WO2018112364A1
(en)
|
2016-12-16 |
2018-06-21 |
Evelo Biosciences, Inc. |
Combination therapies for treating melanoma
|
|
WO2018112360A1
(en)
|
2016-12-16 |
2018-06-21 |
Evelo Biosciences, Inc. |
Combination therapies for treating cancer
|
|
US20190314427A1
(en)
|
2016-12-16 |
2019-10-17 |
Evelo Biosciences, Inc. |
Methods of treating cancer using parabacteroides
|
|
WO2018112365A2
(en)
|
2016-12-16 |
2018-06-21 |
Evelo Biosciences, Inc. |
Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii
|
|
CN110268060B
(zh)
|
2017-01-10 |
2024-07-26 |
箭头药业股份有限公司 |
α-1抗胰蛋白酶(AAT)RNAi物质、包含AAT RNAi物质的组合物和使用方法
|
|
EP3570857A1
(en)
|
2017-01-18 |
2019-11-27 |
Evelo Biosciences, Inc. |
Methods of treating cancer
|
|
EP3570856A2
(en)
|
2017-01-18 |
2019-11-27 |
Evelo Biosciences, Inc. |
Methods of treating cancer
|
|
AU2018213379A1
(en)
|
2017-01-30 |
2019-07-18 |
Arrowhead Pharmaceuticals Inc. |
Compositions and methods for inhibition of factor XII gene expression
|
|
SG11201906728TA
(en)
|
2017-02-06 |
2019-08-27 |
Mpeg La Llc |
Multimeric oligonucleotides having decreased kidney clearance
|
|
JOP20190215A1
(ar)
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
|
MX2019012280A
(es)
|
2017-04-11 |
2020-01-23 |
Arbutus Biopharma Corp |
Composiciones dirigidas.
|
|
WO2018215049A1
(en)
|
2017-05-23 |
2018-11-29 |
F. Hoffmann-La Roche Ag |
Process for galnac oligonucleotide conjugates
|
|
TN2019000308A1
(en)
|
2017-07-06 |
2021-05-07 |
Arrowhead Pharmaceuticals Inc |
RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE
|
|
CA3069451A1
(en)
|
2017-07-13 |
2019-01-17 |
Alnylam Pharmaceuticals, Inc. |
Methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
|
|
TW201920648A
(zh)
|
2017-08-29 |
2019-06-01 |
美商艾弗洛生物科技股份有限公司 |
使用布勞特氏(blautia)菌株治療癌症
|
|
KR20240161202A
(ko)
|
2017-09-11 |
2024-11-12 |
애로우헤드 파마슈티컬스 인코포레이티드 |
아포지단백질 C-III (APOC3)의 발현을 억제하기 위한 RNAi 작용제 및 조성물
|
|
TN2020000038A1
(en)
|
2017-09-14 |
2021-10-04 |
Arrowhead Pharmaceuticals Inc |
Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
|
|
WO2019075419A1
(en)
|
2017-10-13 |
2019-04-18 |
Dicerna Pharmaceuticals, Inc. |
METHODS AND COMPOSITIONS FOR INHIBITING LDHA EXPRESSION
|
|
JP7473472B2
(ja)
|
2017-10-17 |
2024-04-23 |
アローヘッド ファーマシューティカルズ インコーポレイテッド |
アシアロ糖タンパク質受容体１の発現を阻害するためのＲＮＡｉ剤および組成物
|
|
CN110944675B9
(zh)
|
2017-12-01 |
2024-08-09 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
CA3083970A1
(en)
|
2017-12-01 |
2019-06-06 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
|
|
DK3719128T3
(da)
|
2017-12-01 |
2025-03-03 |
Suzhou Ribo Life Science Co Ltd |
Dobbelt-strenget oligonukleotid, sammensætning og konjugat bestaende dobbelt-strenget oligonukleotid, fremgangsmåde herfor og anvendelse heraf
|
|
EP3719127A4
(en)
|
2017-12-01 |
2021-10-20 |
Suzhou Ribo Life Science Co., Ltd. |
NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH IT, MANUFACTURING METHOD AND USE
|
|
EP3719126B1
(en)
|
2017-12-01 |
2025-01-01 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
|
|
US11021692B2
(en)
|
2017-12-19 |
2021-06-01 |
Janssen Sciences Ireland Unlimited Company |
Hepatitis B virus (HBV) vaccines and uses thereof
|
|
AU2018394875B2
(en)
|
2017-12-29 |
2023-08-03 |
Suzhou Ribo Life Science Co., Ltd. |
Conjugates and preparation and use thereof
|
|
AU2019206731A1
(en)
|
2018-01-15 |
2020-07-30 |
Ionis Pharmaceuticals, Inc. |
Modulators of DNM2 expression
|
|
IL276043B2
(en)
*
|
2018-01-29 |
2024-06-01 |
Hoffmann La Roche |
Process for the preparation of galnac oligonucleotide conjugates
|
|
WO2019157531A1
(en)
|
2018-02-12 |
2019-08-15 |
Ionis Pharmaceuticals, Inc. |
Modified compounds and uses thereof
|
|
WO2019169143A1
(en)
|
2018-02-28 |
2019-09-06 |
Evelo Biosciences, Inc. |
Compositions and methods for treating cancer using turicibacter sanguinis
|
|
WO2019169160A1
(en)
|
2018-02-28 |
2019-09-06 |
Evelo Biosciences, Inc. |
Compositions and methods for treating cancer using ruminococcus gnavus
|
|
WO2019169138A1
(en)
|
2018-02-28 |
2019-09-06 |
Evelo Biosciences, Inc. |
Compositions and methods for treating cancer using paraclostridium benzoelyticum
|
|
WO2019169168A1
(en)
|
2018-02-28 |
2019-09-06 |
Evelo Biosciences, Inc. |
Compositions and methods for treating cancer using agathobaculum
|
|
WO2019178057A1
(en)
|
2018-03-12 |
2019-09-19 |
Evelo Biosciences, Inc. |
Methods of treating cancer using burkholderia
|
|
KR102857148B1
(ko)
|
2018-04-05 |
2025-09-11 |
사일런스 테라퓨틱스 게엠베하 |
안티센스 가닥의 5' 단부에 비닐포스포네이트를 갖는 siRNA
|
|
MX2020011570A
(es)
|
2018-05-07 |
2020-11-24 |
Alnylam Pharmaceuticals Inc |
Administracion extrahepatica.
|
|
US12005120B2
(en)
|
2018-05-08 |
2024-06-11 |
Regulus Therapeutics Inc. |
Galnac conjugated modified oligonucleotides as miR-122 inhibitor having HCV antiviral activity with reduced hyperbilirubinemia side-effect
|
|
CU20200082A7
(es)
|
2018-05-09 |
2021-06-08 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para la reducción de la expresión de fxi
|
|
US12496311B2
(en)
|
2018-07-17 |
2025-12-16 |
Aronora, Inc. |
Methods for safely reducing thrombopoietin
|
|
JP2021531278A
(ja)
|
2018-07-20 |
2021-11-18 |
レグルス セラピューティクス インコーポレイテッド |
オリゴヌクレオチドの経口送達のための方法
|
|
EP3833397A4
(en)
|
2018-08-08 |
2023-06-14 |
Arcturus Therapeutics, Inc. |
COMPOSITIONS AND AGENTS AGAINST NON-ALCOHOLIC STEATOHEPATITIS
|
|
WO2020038377A1
(zh)
|
2018-08-21 |
2020-02-27 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的药物组合物和缀合物及其用途
|
|
US11273137B2
(en)
|
2018-09-04 |
2022-03-15 |
Board Of Trustees Of Michigan State University |
Methods and compositions to prevent and treat disorders associated with mutations in the ODC1 gene
|
|
KR102769565B1
(ko)
|
2018-09-19 |
2025-02-20 |
애로우헤드 파마슈티컬스 인코포레이티드 |
17베타-HSD 유형 13- (HSD17B13)의 발현을 억제하기 위한 RNAi 작용제, 그의 조성물, 및 사용 방법
|
|
TW202542311A
(zh)
|
2018-09-19 |
2025-11-01 |
美商Ionis製藥公司 |
Pnpla3表現之調節劑
|
|
US11896674B2
(en)
|
2018-09-30 |
2024-02-13 |
Suzhou Ribo Life Science Co., Ltd. |
SiRNA conjugate, preparation method therefor and use thereof
|
|
CR20210395A
(es)
|
2018-12-21 |
2021-11-05 |
Ionis Pharmaceuticals Inc |
Moduladores de la expresión de hsd17b13
|
|
WO2020135673A1
(zh)
*
|
2018-12-28 |
2020-07-02 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
WO2020135581A1
(zh)
*
|
2018-12-28 |
2020-07-02 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
SG11202105577TA
(en)
|
2019-01-09 |
2021-06-29 |
Arrowhead Pharmaceuticals Inc |
Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use
|
|
WO2020163747A1
(en)
|
2019-02-07 |
2020-08-13 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for hepatitis b virus infection
|
|
CA3132199A1
(en)
|
2019-03-12 |
2020-09-17 |
President And Fellows Of Harvard College |
Methods and compositions for treating cancer
|
|
CA3132170A1
(en)
|
2019-04-18 |
2020-10-22 |
Michael BIERMER |
Combination therapy for treating hepatitis b virus infection
|
|
US20200332297A1
(en)
|
2019-04-18 |
2020-10-22 |
Janssen Pharmaceuticals, Inc. |
Combination therapy for treating hepatitis b virus infection
|
|
US11510939B1
(en)
|
2019-04-19 |
2022-11-29 |
Apellis Pharmaceuticals, Inc. |
RNAs for complement inhibition
|
|
US12590304B2
(en)
|
2019-05-22 |
2026-03-31 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
|
|
KR20220011689A
(ko)
|
2019-05-22 |
2022-01-28 |
쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 |
핵산, 약제학적 조성물, 접합체, 제조 방법, 및 용도
|
|
AU2020280439B2
(en)
|
2019-05-22 |
2025-08-14 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
|
|
CN113795582B
(zh)
|
2019-05-24 |
2024-05-24 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
MX2021015003A
(es)
|
2019-06-06 |
2022-01-24 |
Arrowhead Pharmaceuticals Inc |
Metodos para el tratamiento de la deficiencia de alfa-1 antitripsina (aatd).
|
|
US20220226269A1
(en)
|
2019-06-12 |
2022-07-21 |
President And Fellows Of Harvard College |
Methods and compositions for modulation of an interspecies gut bacterial pathway for levodopa metabolism
|
|
KR20220042116A
(ko)
|
2019-06-18 |
2022-04-04 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
B형 간염 바이러스(HBV) 백신 및 HBV-타케팅 RNAi의 조합
|
|
CA3143679A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
|
|
CN110218728A
(zh)
*
|
2019-06-28 |
2019-09-10 |
厦门甘宝利生物医药有限公司 |
一种新化合物及其应用
|
|
JP2022543191A
(ja)
*
|
2019-07-30 |
2022-10-11 |
エムペグ エルエイ リミテッド ライアビリティ カンパニー |
増強された生理活性を有する多量体オリゴヌクレオチドの皮下送達
|
|
WO2021022110A1
(en)
|
2019-08-01 |
2021-02-04 |
Evelo Biosciences, Inc. |
Inducing immune effects using bacteria of the genus bifidobacterium
|
|
WO2021074772A1
(en)
|
2019-10-14 |
2021-04-22 |
Astrazeneca Ab |
Modulators of pnpla3 expression
|
|
US20230054711A1
(en)
*
|
2019-12-31 |
2023-02-23 |
Xiamen University |
Multimerization delivery system for intracellular delivery of molecule
|
|
US20230070129A1
(en)
|
2020-01-06 |
2023-03-09 |
Seasun Therapeutics |
Composition for preventing or treating macular degeneration, containing cell permeable nucleic acid complex as active ingredient
|
|
CN120505310A
(zh)
|
2020-02-28 |
2025-08-19 |
Ionis制药公司 |
用于调节smn2的化合物和方法
|
|
KR20230004456A
(ko)
|
2020-03-04 |
2023-01-06 |
리제너론 파아마슈티컬스, 인크. |
면역 요법에 대한 종양 세포의 감작화를 위한 방법 및 조성물
|
|
US20210285000A1
(en)
|
2020-03-05 |
2021-09-16 |
Janssen Pharmaceuticals, Inc. |
Combination therapy for treating hepatitis b virus infection
|
|
AR121672A1
(es)
|
2020-03-26 |
2022-06-29 |
Arrowhead Pharmaceuticals Inc |
AGENTES DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3, COMPOSICIONES FARMACÉUTICAS DE ESTA, Y MÉTODOS DE USO
|
|
CN115916262A
(zh)
|
2020-04-21 |
2023-04-04 |
旗舰创业股份有限公司 |
双官能分子及其使用方法
|
|
EP4157264A4
(en)
|
2020-05-27 |
2024-06-19 |
The Regents of the University of California |
COMPOSITIONS AND METHODS FOR CELL TRANSDIFFERENTIATION
|
|
EP4168547A1
(en)
|
2020-06-22 |
2023-04-26 |
Janssen Pharmaceuticals, Inc. |
Compositions and methods for treatment of hepatitis d virus infection
|
|
CA3189065A1
(en)
|
2020-09-11 |
2022-03-17 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of dux4, compositions thereof, and methods of use
|
|
CN116348150A
(zh)
|
2020-09-11 |
2023-06-27 |
箭头药业股份有限公司 |
用于递送治疗剂的脂质缀合物
|
|
MX2023002939A
(es)
|
2020-09-11 |
2023-04-11 |
Arrowhead Pharmaceuticals Inc |
Plataformas para el transporte de farmacos hacia el musculo esqueletico y metodos de uso.
|
|
WO2022056454A2
(en)
|
2020-09-14 |
2022-03-17 |
President And Fellows Of Harvard College |
Methods and compositions for treating hpv-positive cancers
|
|
AU2021344422A1
(en)
|
2020-09-16 |
2023-05-04 |
Gordon J. Freeman |
Methods of treating an individual that has failed an anti-pd-1/anti-pd-l1 therapy
|
|
LT4136092T
(lt)
|
2020-11-18 |
2024-09-25 |
Ionis Pharmaceuticals, Inc. |
Junginiai ir būdai, skirti angiotenzinogeno raiškos moduliavimui
|
|
TW202245809A
(zh)
|
2020-12-18 |
2022-12-01 |
美商詹森藥物公司 |
用於治療b型肝炎病毒感染之組合療法
|
|
WO2022152869A1
(en)
|
2021-01-15 |
2022-07-21 |
Janssen Sciences Ireland Unlimited Company |
Use of oligonucleotides for individuals with hepatic impairment
|
|
CN114767704B
(zh)
*
|
2021-01-21 |
2024-06-14 |
圣诺制药公司 |
一种能够靶向乙型肝炎病毒的药物构造及药物组合物
|
|
JP2024516096A
(ja)
|
2021-04-08 |
2024-04-12 |
アローヘッド ファーマシューティカルズ インコーポレイテッド |
終末糖化産物受容体の発現を阻害するためのＲＮＡｉ剤、その組成物、及び使用方法
|
|
MX2023014026A
(es)
|
2021-05-28 |
2023-12-12 |
Arrowhead Pharmaceuticals Inc |
Agentes de rnai para inhibir la expresion de mucina 5ac (muc5ac), composiciones de estos y metodos de uso.
|
|
US11629349B2
(en)
|
2021-06-21 |
2023-04-18 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
|
|
JP2024527380A
(ja)
|
2021-07-09 |
2024-07-24 |
グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー３）、リミテッド |
腎機能障害を有する個体へのオリゴヌクレオチドの使用
|
|
US12042509B2
(en)
|
2021-10-01 |
2024-07-23 |
Adarx Pharmaceuticals, Inc. |
Prekallikrein-modulating compositions and methods of use thereof
|
|
PE20241353A1
(es)
|
2021-11-09 |
2024-07-03 |
Viaqua Therapeutics Ltd |
Composiciones para acuicultura
|
|
US20250230412A1
(en)
|
2022-02-01 |
2025-07-17 |
President And Fellows Of Harvard College |
Methods and compositions for treating cancer
|
|
WO2023233290A1
(en)
|
2022-05-31 |
2023-12-07 |
Janssen Sciences Ireland Unlimited Company |
Rnai agents targeting pd-l1
|
|
JP2025522433A
(ja)
|
2022-06-15 |
2025-07-15 |
アローヘッド ファーマシューティカルズ インコーポレイテッド |
スーパーオキシドジスムターゼ１（ＳＯＤ１）の発現を阻害するためのＲＮＡｉ剤、その組成物、及び使用の方法
|
|
WO2024151942A2
(en)
|
2023-01-13 |
2024-07-18 |
Hemoshear Therapeutics, Inc. |
Sirnas targeting slc10a1 transcripts, compositions and uses thereof
|
|
EP4684015A2
(en)
|
2023-03-21 |
2026-01-28 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of complement factor b (cfb), pharmaceutical compositions thereof, and methods of use
|
|
TW202448484A
(zh)
|
2023-04-20 |
2024-12-16 |
美商雅迪克斯製藥公司 |
Ｍａｐｔ調節組合物及其使用方法
|
|
WO2024238396A1
(en)
|
2023-05-12 |
2024-11-21 |
Adarx Pharmaceuticals, Inc. |
Nmda ligand conjugated compounds and uses thereof
|
|
CN121335980A
(zh)
|
2023-05-26 |
2026-01-13 |
阿达尔克斯制药有限公司 |
Sod1调节组合物及其使用方法
|
|
EP4731763A1
(en)
|
2023-06-20 |
2026-04-29 |
Adarx Pharmaceuticals, Inc. |
Lrrk2-modulating compositions and methods of use thereof
|
|
WO2025038750A2
(en)
|
2023-08-14 |
2025-02-20 |
President And Fellows Of Harvard College |
Methods and compositions for treating cancer
|
|
IL326882A
(en)
|
2023-08-30 |
2026-04-01 |
Arrowhead Pharmaceuticals Inc |
RNAi agents for inhibiting expression of inhibitory subunit beta E (INHBE), their pharmaceutical compositions and methods of use
|
|
WO2025072748A2
(en)
|
2023-09-29 |
2025-04-03 |
Insitro, Inc. |
Compositions and methods for treating nonalcoholic fatty liver disease
|
|
WO2025090926A1
(en)
*
|
2023-10-26 |
2025-05-01 |
The Penn State Research Foundation |
Ultrasound-sensitive peptide particles with surface-bound gene editing tools for spatially resolved molecule delivery
|
|
WO2025137384A1
(en)
|
2023-12-20 |
2025-06-26 |
Arrowhead Pharmaceuticals, Inc. |
Methods and reagents for improved oligonucleotide synthesis
|
|
WO2025155911A1
(en)
|
2024-01-18 |
2025-07-24 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of hurler syndrome
|
|
US12553050B2
(en)
|
2024-03-22 |
2026-02-17 |
Takeda Pharmaceutical Company Limited |
Compositions and methods for inhibiting cytochrome P450 family 7 subfamily a member 1 (CYP7A1) expression
|
|
US12551569B2
(en)
|
2024-03-31 |
2026-02-17 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of microtubule associated protein tau (MAPT), compositions thereof, and methods of use
|
|
GB202404661D0
(en)
|
2024-04-02 |
2024-05-15 |
Proqr Therapeutics Ii Bv |
Antisense oligoncleotides for the treatment of liver disease
|
|
WO2025224230A1
(en)
|
2024-04-25 |
2025-10-30 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of fatty liver disease
|
|
WO2025226980A2
(en)
|
2024-04-25 |
2025-10-30 |
Insitro, Inc. |
Compositions and methods for treating metabolic dysfunction-associated steatotic liver disease
|
|
WO2025242321A1
(en)
|
2024-05-24 |
2025-11-27 |
Glaxosmithkline Intellectual Property (No.3) Limited |
Novel use
|
|
WO2025265013A2
(en)
|
2024-06-20 |
2025-12-26 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of huntingtin (htt), compositions thereof, and methods of use
|
|
GB202410081D0
(en)
|
2024-07-11 |
2024-08-28 |
Proqr Therapeutics Ii Bv |
Antisense oligonucleotides for the treatment of cardiovascular disease
|
|
US20260015617A1
(en)
|
2024-07-12 |
2026-01-15 |
Novartis Ag |
DOUBLE STRANDED RNAi AGENTS, COMPOSITIONS AND METHODS OF USE
|
|
WO2026044017A2
(en)
|
2024-08-21 |
2026-02-26 |
Insitro, Inc. |
Compositions and methods for treating nonalcoholic fatty liver disease
|